Federal Register / Vol. -57,-No. 166 / Wednesday, August 26, 1992 / Notices 
38737 
with renal cell carcinoma who are HLA- 
A2 positive and who have failed 
conventional therapy. This Phase I study 
will examine whether allogeneic HLA- 
A2 matched renal cell carcinoma cells 
expressing recombinant human 
Interleukin-2 (IL-2) can be injected 
subcutaneously and used to create a 
potent tumor specific immune response, 
without producing toxicity. By allowing 
the tumor cells to present the MHC 
Class I molecule as well as the secreted 
IL-2, a clonal expansion of tumor 
specific effector cells is expected. These 
effector populations may access residual 
tumor at distant sites via the systemic 
circulation.” 
OMB's “Mandatory Information 
Requirements for Federal Assistance 
Program Announcements" (45 FR 39592) 
requires a statement concerning the 
official government programs contained 
in the Catalog of Federal Domestic 
Assistance. Normally NIH lists in its 
announcements the number and title of 
affected individual programs for the 
guidance of the public. Because the 
guidance in this notice covers not only 
virtually every NIH program but also 
essentially every Federal research 
program in which DNA recombinant 
molecule techniques could be used, it 
has been determined to be not cost 
effective or in the public interest to 
attempt to list these programs. Such a 
list would likely require several 
additional pages. In addition, NIH could 
not be certain that every Federal 
program would be included as many 
Federal agencies, as well as private 
organizations, both national and 
international, have elected to follow the 
NIH Guidelines. In lieu of the individual 
program listing, NIH invites readers to 
direct questions to the information 
address above about whether individual 
programs listed in the Catalog of Federal 
Domestic Assistance are affected. 
Effective date: August 14, 1992. 
Bemadine Healy, 
Director, National Institutes of Health. 
[FR Doc. 92-20389 Filed 8-25-92; 8:45 am) 
B1UJMQ CODE 4140-01-M 
Recombinant DNA Research, Volume 16 
[213] 
